^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Basal Cell Carcinoma

    Related cancers:
    1d
    Depicting the Immunological Landscape of Basal Cell Carcinoma Subtypes. (PubMed, J Cutan Pathol)
    Our findings support previous reports on the immune-privileged status of BCC. Contrary to the literature, we could not confirm PD-L1 expression on BCC cells, but rather on the intra- and peritumoral immune cells. Given these results and the literature suggesting a tendency of higher immunoreactivity compared to other BCC subtypes, basosquamous BCC might be a better target for anti-PD-1 therapy as opposed to other subtypes.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • SOX9 (SRY-Box Transcription Factor 9) • ITGAX (Integrin Subunit Alpha X)
    |
    PD-L1 expression • PD-L1 negative
    |
    Libtayo (cemiplimab-rwlc)
    3d
    Revealing key biomarkers and molecular mechanisms associated with di(2-ethylhexyl) phthalate in skin cancer. (PubMed, Front Mol Biosci)
    Collectively, this study systematically elucidates the toxicological mechanism by which DEHP promotes skin cancer development through subtype-specific pathways regulated by 11 key targets, clarifying its direct binding patterns with core targets and downstream pathway disruption characteristics. This not only fills a research gap in the molecular mechanisms of DEHP-induced skin carcinogenesis but also provides novel biomarkers for environmental exposure prevention and targeted interventions against skin cancer.
    Journal • IO biomarker
    |
    ER (Estrogen receptor) • BCL2 (B-cell CLL/lymphoma 2) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CCND1 (Cyclin D1) • IL6 (Interleukin 6) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CASP3 (Caspase 3)
    3d
    The diagnostic and prognostic utility of engrailed homeobox 1 and MYB immunohistochemical expression in the differentiation of salivary gland adenoid cystic carcinoma from its mimics. (PubMed, Rev Esp Patol)
    EN1 is a highly sensitive marker for AdCC and has prognostic value. MYB is a useful complementary marker, particularly when polymorphous adenocarcinoma is a consideration.
    Journal
    |
    MYB (MYB Proto-Oncogene, Transcription Factor)
    6d
    Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors (clinicaltrials.gov)
    P1, N=25, Recruiting, University of California, Irvine
    New P1 trial
    8d
    SWOG S1609: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (clinicaltrials.gov)
    P2, N=798, Active, not recruiting, National Cancer Institute (NCI) | Trial primary completion date: May 2027 --> May 2026
    Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    PD-L1 overexpression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)
    9d
    L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC) (clinicaltrials.gov)
    P2, N=180, Recruiting, Philogen S.p.A. | Not yet recruiting --> Recruiting | Initiation date: Feb 2026 --> Jun 2026
    Enrollment open • Trial initiation date
    |
    Nidlegy (darleukin/fibromun) • darleukin (L19IL2)
    9d
    SONIBEC: Tailored Sonidegib Schedule After Complete Response in BCC (clinicaltrials.gov)
    P2, N=21, Active, not recruiting, Gruppo Oncologico del Nord-Ovest | Recruiting --> Active, not recruiting | Trial completion date: Jan 2026 --> Dec 2026
    Enrollment closed • Trial completion date • Compliance
    |
    Odomzo (sonidegib)
    9d
    Alteration of the Immune Microenvironment in Basal Cell Carcinoma Following Photodynamic Therapy (clinicaltrials.gov)
    P2, N=18, Active, not recruiting, Case Comprehensive Cancer Center | Recruiting --> Active, not recruiting | N=28 --> 18
    Enrollment closed • Enrollment change
    10d
    Pilot Study of Line-Field Confocal Optical Coherence Tomography for Detection of Mohs Micrographic Surgery Margins of Basal Cell Carcinomas (clinicaltrials.gov)
    P=N/A, N=60, Recruiting, Roswell Park Cancer Institute | Trial completion date: Dec 2026 --> Jun 2027 | Trial primary completion date: Dec 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    10d
    Two inflammasomes as tumour markers for nonmelanocytic skin cancer: new hopes for early detection and targeted therapy. (PubMed, Skin Health Dis)
    A role in inflammation or tumour growth and metastasis provides a good rationale for early detection and prognosis, and targeted clinical applications. This study identifies NLRP1 and NLRP3 inflammasomes as potential biomarkers and therapeutic targets in NMSC, linking their altered expression to tumour progression and recurrence.
    Review • Journal
    |
    NLRP3 (NLR Family Pyrin Domain Containing 3)
    12d
    Basal Cell Carcinoma With Ductal Differentiation Presenting as a Large Unilocular Cyst on the Abdomen. (PubMed, J Cutan Pathol)
    BCC with ductal differentiation has been reported, but cases with large unilocular cysts are uncommon. This case broadens the histologic spectrum of BCC and emphasizes the importance of complete excision and comprehensive immunohistochemical analysis in cystic lesions to avoid misdiagnosis.
    Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • YBX1 (Y-Box Binding Protein 1)
    12d
    Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers (clinicaltrials.gov)
    P=N/A, N=20, Active, not recruiting, University of Wisconsin, Madison | Recruiting --> Active, not recruiting
    Enrollment closed